Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Biofrontera (BFRI) over the last 6 years, with Q3 2025 value amounting to $285000.0.

  • Biofrontera's Gains from Investment Securities fell 5808.82% to $285000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $461000.0, marking a year-over-year increase of 10797.03%. This contributed to the annual value of $1.4 million for FY2024, which is 126573.79% up from last year.
  • Biofrontera's Gains from Investment Securities amounted to $285000.0 in Q3 2025, which was down 5808.82% from -$153000.0 recorded in Q2 2025.
  • In the past 5 years, Biofrontera's Gains from Investment Securities registered a high of $1.8 billion during Q3 2022, and its lowest value of -$5.4 million during Q2 2024.
  • Over the past 5 years, Biofrontera's median Gains from Investment Securities value was $77948.0 (recorded in 2023), while the average stood at $214.8 million.
  • In the last 5 years, Biofrontera's Gains from Investment Securities surged by 8157390000.0% in 2022 and then plummeted by 135013.33% in 2024.
  • Quarter analysis of 5 years shows Biofrontera's Gains from Investment Securities stood at $12.8 million in 2021, then crashed by 108.76% to -$1.1 million in 2022, then plummeted by 297.41% to -$4.5 million in 2023, then surged by 92.12% to -$351000.0 in 2024, then soared by 181.2% to $285000.0 in 2025.
  • Its Gains from Investment Securities stands at $285000.0 for Q3 2025, versus -$153000.0 for Q2 2025 and $1.3 million for Q1 2025.